Given that treatment with the ROCK inhibitor Y-27632 prevents anoikis [13], tumor cells harboring the ROCK1 nonsense mutation might be resistant to anoikis through the impairment of the Rho-ROCK pathway, similar to tumor cells harboring the RHOA L57V mutation. The gene discussed is ROCK1; the disease is neoplasm.